Portfolio Company

Coramaze

Coramaze

Coramaze invented the Tripair® valve repair system for treatment of functional Tricuspid Regurgitation

2017

Year invested

Fund I

MTIP Fund

Israel, Germany

Location

Active Investment

Investment status

Heart Valves

Segment

Coramaze

Overview

CoramazeTechnologies develops Tripair®, a valve repair system designed for the treatment of functional Tricuspid Regurgitation (fTR) in heart failure patients. fTR represents a high unmet medical need, with a large majority of patients left with no therapeutic option. Coramaze’s minimally invasive procedure aims to improve quality of life and reduce morbidity.

Great Ideas. Long-term results.

Investments that
make a difference.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Media

Trends and insights
from our health experts.

Contact

You would like to invest
into the next big thing?

As a long-term investor with a track record of creating successful and sustainable businesses, our goal is to deliver attractive strategic and financial returns to our investors.

Bubble